MedTrace Logo

Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma

NCT05806580 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2024-10-23

No results posted yet for this study

Summary

To observe the efficacy and safety of a second infusion of relma-cel injection in patients with relapsed or refractory B-cell lymphoma.

Conditions

  • Relapsed or Refractory B-cell Lymphoma

Interventions

DRUG

Relma-cel

Patients who have undergone at least one disease assessment after initial Relma-cel treatment and have not achieved complete remission may receive a second treatment based on clinical practice. The specific dosage will be determined by the investigator according to the patient's condition and available dose reserves.

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2027-05-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05806580 on ClinicalTrials.gov